FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808436617> ?p ?o ?g. }

• W2808436617 endingPage "e0198514" @default.
• W2808436617 startingPage "e0198514" @default.
• W2808436617 abstract "The principal finding from this study was the recognition that the α-adrenergic antagonist, phenoxybenzamine, possesses histone deacetylase inhibitory activity. Phenoxybenzamine is approved by the United States Food and Drug Administration for the treatment of hypertensive crises associated with tumors of the adrenal medulla, pheochromocytomas. It has several off label indications relative to its capacity to relax vascular smooth muscle and smooth muscle of the urogenital tract. The drug also has a long history of apparent efficacy in ameliorating, and perhaps reversing, the severe symptoms of neuropathic pain syndromes. Our interest in this feature of the drug relates to the fact that certain types of neuropathic pain, in particular complex regional pain syndrome, demonstrate a proliferative nature, with the capacity to spread from an injured limb, for example, to a non-injured limb and perhaps to essentially the entire body. Sensory neuronal sprouting in the spinal cord has been observed under conditions where there is a high sensory input from painful stimuli. Searches of gene expression signatures in the BroadBuild02 Molecular Signature Database using their connectivity map software suggested that phenoxybenzamine may have histone deacetylase inhibitory activity. Studies by others have reported inhibitory effects of phenoxybenzamine on growth, invasion and migration of human tumor cell cultures and, in one study, inhibition of tumor expansion in animal experiments. Inhibitory effects on human tumor cell cultures are also reported in the present study. Phenoxybenzamine was also found to have histone deacetylase inhibitory activity; histone deacetylase isoforms 5, 6, and 9 were the most sensitive to inhibition by phenoxybenzamine. The importance of elevated levels of these isoforms as biomarkers of poor prognosis in human malignant disease, and the recognized suppression of tumor growth that may accrue from their inhibition, opens consideration of possible translation of phenoxybenzamine to new clinical applications. This might be facilitated by the fact that phenoxybenzamine is already an approved drug entity. There appears to be no previous report of the activity of phenoxybenzamine as a histone deacetylase inhibitor." @default.
• W2808436617 created "2018-06-21" @default.
• W2808436617 creator A5035574699 @default.
• W2808436617 date "2018-06-13" @default.
• W2808436617 modified "2023-10-14" @default.
• W2808436617 title "Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases" @default.
• W2808436617 cites W1748121091 @default.
• W2808436617 cites W1897662255 @default.
• W2808436617 cites W1914090025 @default.
• W2808436617 cites W1920958927 @default.
• W2808436617 cites W1966731347 @default.
• W2808436617 cites W1973348591 @default.
• W2808436617 cites W1974113889 @default.
• W2808436617 cites W1974535994 @default.
• W2808436617 cites W1984006732 @default.
• W2808436617 cites W1993828402 @default.
• W2808436617 cites W1995919174 @default.
• W2808436617 cites W1996723076 @default.
• W2808436617 cites W1997468352 @default.
• W2808436617 cites W2016724097 @default.
• W2808436617 cites W2018003892 @default.
• W2808436617 cites W2023849337 @default.
• W2808436617 cites W2029980980 @default.
• W2808436617 cites W2030722141 @default.
• W2808436617 cites W2032033480 @default.
• W2808436617 cites W2048347471 @default.
• W2808436617 cites W2063944387 @default.
• W2808436617 cites W2065447003 @default.
• W2808436617 cites W2066264051 @default.
• W2808436617 cites W2068785251 @default.
• W2808436617 cites W2080605611 @default.
• W2808436617 cites W2093244800 @default.
• W2808436617 cites W2098383913 @default.
• W2808436617 cites W2099457443 @default.
• W2808436617 cites W2099635542 @default.
• W2808436617 cites W2105095164 @default.
• W2808436617 cites W2118837528 @default.
• W2808436617 cites W2121463325 @default.
• W2808436617 cites W2121604817 @default.
• W2808436617 cites W2122092872 @default.
• W2808436617 cites W2130410032 @default.
• W2808436617 cites W2136489807 @default.
• W2808436617 cites W2141203994 @default.
• W2808436617 cites W2146729012 @default.
• W2808436617 cites W2147203601 @default.
• W2808436617 cites W2160890617 @default.
• W2808436617 cites W2163982678 @default.
• W2808436617 cites W2165455805 @default.
• W2808436617 cites W2375921487 @default.
• W2808436617 cites W2409078925 @default.
• W2808436617 cites W2561198532 @default.
• W2808436617 cites W2589497087 @default.
• W2808436617 cites W2593043086 @default.
• W2808436617 cites W32765225 @default.
• W2808436617 cites W2142035548 @default.
• W2808436617 doi "https://doi.org/10.1371/journal.pone.0198514" @default.
• W2808436617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5999115" @default.
• W2808436617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29897996" @default.
• W2808436617 hasPublicationYear "2018" @default.
• W2808436617 type Work @default.
• W2808436617 sameAs 2808436617 @default.
• W2808436617 citedByCount "8" @default.
• W2808436617 countsByYear W28084366172019 @default.
• W2808436617 countsByYear W28084366172022 @default.
• W2808436617 countsByYear W28084366172023 @default.
• W2808436617 crossrefType "journal-article" @default.
• W2808436617 hasAuthorship W2808436617A5035574699 @default.
• W2808436617 hasBestOaLocation W28084366171 @default.
• W2808436617 hasConcept C104317684 @default.
• W2808436617 hasConcept C126322002 @default.
• W2808436617 hasConcept C134018914 @default.
• W2808436617 hasConcept C169760540 @default.
• W2808436617 hasConcept C170493617 @default.
• W2808436617 hasConcept C2776202225 @default.
• W2808436617 hasConcept C2778305200 @default.
• W2808436617 hasConcept C2780668150 @default.
• W2808436617 hasConcept C502942594 @default.
• W2808436617 hasConcept C54355233 @default.
• W2808436617 hasConcept C64927066 @default.
• W2808436617 hasConcept C71924100 @default.
• W2808436617 hasConcept C86803240 @default.
• W2808436617 hasConcept C98274493 @default.
• W2808436617 hasConceptScore W2808436617C104317684 @default.
• W2808436617 hasConceptScore W2808436617C126322002 @default.
• W2808436617 hasConceptScore W2808436617C134018914 @default.
• W2808436617 hasConceptScore W2808436617C169760540 @default.
• W2808436617 hasConceptScore W2808436617C170493617 @default.
• W2808436617 hasConceptScore W2808436617C2776202225 @default.
• W2808436617 hasConceptScore W2808436617C2778305200 @default.
• W2808436617 hasConceptScore W2808436617C2780668150 @default.
• W2808436617 hasConceptScore W2808436617C502942594 @default.
• W2808436617 hasConceptScore W2808436617C54355233 @default.
• W2808436617 hasConceptScore W2808436617C64927066 @default.
• W2808436617 hasConceptScore W2808436617C71924100 @default.
• W2808436617 hasConceptScore W2808436617C86803240 @default.
• W2808436617 hasConceptScore W2808436617C98274493 @default.
• W2808436617 hasIssue "6" @default.
• W2808436617 hasLocation W28084366171 @default.

• next